Authors: Jin H, Dong Y, Huang C, Wang D, He Z, Shen L, Ma C, Wang Z, Shi S, Shuai B.
DOI: 10.3389/fsurg.2025.1582180
Abstract Summary
Meta-analysis of 13 studies (4,420 patients) reveals teriparatide outperforms bisphosphonates for osteoporosis treatment. Teriparatide significantly reduced vertebral and non-vertebral fracture risks while delivering superior bone mineral density improvements at both lumbar spine and femoral neck sites, with benefits sustained beyond 18 months. Importantly, adverse event rates were comparable between treatments.
Why Brain? ðŸ§
Teriparatide proves more effective than bisphosphonates for preventing fractures and improving bone density in osteoporosis patients, with similar safety profiles, offering a superior treatment option.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
